{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:06:57Z","timestamp":1789160817258,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032637","name":"Newron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032121","name":"Lundbeck USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, & Immunity - Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbih.2026.101342","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:35:23Z","timestamp":1788305723000},"page":"101342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cytokine and C-reactive protein concentrations over 6 months of treatment with clozapine in treatment resistant schizophrenia"],"prefix":"10.1016","volume":"56","author":[{"given":"Katherine","family":"Embleton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-064X","authenticated-orcid":false,"given":"Alice","family":"Egerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bbih.2026.101342_bib1","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1038\/npp.2015.90","article-title":"Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment","volume":"40","author":"Ahmed","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbih.2026.101342_bib2","article-title":"Smoking status effect on inflammatory markers in a randomized trial of current and former heavy smokers","volume":"2015","author":"Aldaham","year":"2015","journal-title":"Int. J. Inflamm."},{"issue":"7","key":"10.1016\/j.bbih.2026.101342_bib3","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2174\/1570159X22666231128101725","article-title":"Immunomodulatory effects of clozapine: more than just a side effect in schizophrenia","volume":"22","author":"Amerio","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bbih.2026.101342_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2024.12.010","article-title":"Sub-clinical systemic inflammation as a determinant of admission duration in psychosis","volume":"276","author":"Blackman","year":"2025","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.bbih.2026.101342_bib5","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00213-022-06138-0","article-title":"Changes in corticostriatal connectivity and striatal tissue iron associated with efficacy of clozapine for treatment-resistant schizophrenia","volume":"239","author":"Blazer","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12888-023-05397-1","article-title":"CLEAR - Clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings","volume":"24","author":"Casetta","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.bbih.2026.101342_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11481-013-9460-x","article-title":"Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain","volume":"8","author":"Chang","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.bbih.2026.101342_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2023.03.014","article-title":"Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia","volume":"72","author":"Chen","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.bbih.2026.101342_bib9","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/s41380-025-03337-x","article-title":"Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences","volume":"31","author":"Deakin","year":"2026","journal-title":"Mol. Psychiatr."},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41537-024-00469-x","article-title":"Association of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome","volume":"10","author":"Dong","year":"2024","journal-title":"Schizophrenia (Heidelb)"},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/acps.13416","article-title":"Inflammation in first-episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis","volume":"146","author":"Dunleavy","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbih.2026.101342_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2020.12.020","article-title":"Peripheral immune markers and antipsychotic non-response in psychosis","volume":"230","author":"Enache","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbih.2026.101342_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.602121","article-title":"Association between SIRT1, cytokines, and metabolic syndrome in schizophrenia patients with olanzapine or clozapine monotherapy","volume":"11","author":"Fang","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.bbih.2026.101342_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bbi.2023.05.005","article-title":"The association between peripheral inflammation, brain glutamate and antipsychotic response in schizophrenia: data from the STRATA collaboration","volume":"111","author":"Fenn-Moltu","year":"2023","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.bbih.2026.101342_bib15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol. Psychiatr."},{"issue":"3","key":"10.1016\/j.bbih.2026.101342_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067944","article-title":"Protocol for the psychosis immune mechanism stratified medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis","volume":"13","author":"Foley","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41398-024-03102-8","article-title":"Longitudinal changes in DNA methylation associated with clozapine use in treatment-resistant schizophrenia from two international cohorts","volume":"14","author":"Gillespie","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbih.2026.101342_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030577","article-title":"Clozapine prevents poly (I:C) induced inflammation by modulating NLRP3 pathway in microglial cells","volume":"9","author":"Giridharan","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.bbih.2026.101342_bib19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.bbih.2026.101342_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbi.2023.10.001","article-title":"Changes in immunoglobulin levels during clozapine treatment in schizophrenia","volume":"115","author":"Griffiths","year":"2024","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.bbih.2026.101342_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002139900351","article-title":"Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight","volume":"149","author":"Hinze-Selch","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbih.2026.101342_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","article-title":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - a comprehensive systematic review and meta-analysis","volume":"90","author":"Jeppesen","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-026-03967-x","article-title":"Magnetic resonance texture alterations in the caudate nucleus following 18 weeks of clozapine treatment in patients with treatment-resistant schizophrenia","volume":"16","author":"Jo","year":"2026","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbih.2026.101342_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbih.2026.101342_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2026.1674","article-title":"Neurometabolites and antipsychotic response in psychosis: a mega-analysis","author":"King","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbih.2026.101342_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.612471","article-title":"The role of peripheral inflammation in clinical outcome and brain imaging abnormalities in psychosis: a systematic review","volume":"12","author":"Kose","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41537-022-00230-2","article-title":"Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia","volume":"8","author":"Krajner","year":"2022","journal-title":"npj Schizophr."},{"issue":"4","key":"10.1016\/j.bbih.2026.101342_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/YIC.0000000000000303","article-title":"Low levels of serum vitamin D in clozapine-treated schizophrenia patients are associated with high levels of the proinflammatory cytokine IL-6","volume":"35","author":"Krivoy","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib30","article-title":"Immune signatures of treatment-resistant schizophrenia: a FondaMental academic centers of expertise for schizophrenia (FACE-SZ) study","volume":"2","author":"Leboyer","year":"2021","journal-title":"Schizophr Bull Open"},{"issue":"12","key":"10.1016\/j.bbih.2026.101342_bib31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/phar.2887","article-title":"A systematic review of clozapine-associated inflammation and related monitoring","volume":"43","author":"Leung","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.bbih.2026.101342_bib32","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00406-024-01885-x","article-title":"Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients","volume":"275","author":"Li","year":"2025","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.bbih.2026.101342_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbi.2023.07.014","article-title":"Peripheral inflammatory subgroup differences in anterior default mode network and multiplex functional network topology are associated with cognition in psychosis","volume":"114","author":"Lizano","year":"2023","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.bbih.2026.101342_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/a-2290-6386","article-title":"Blood cell count ratios at baseline are associated with initial clinical response to clozapine in treatment-resistant, clozapine-naive, schizophrenia-spectrum disorder","volume":"57","author":"Llorca-Bofi","year":"2024","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.bbih.2026.101342_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0924-977X(99)00062-0","article-title":"Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics","volume":"10","author":"Maes","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.bbih.2026.101342_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.bbih.2026.101342_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.bbih.2026.101342_bib38","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/schbul\/sbaa156","article-title":"Changes in brain glutamate on switching to clozapine in treatment-resistant schizophrenia","volume":"47","author":"McQueen","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.bbih.2026.101342_bib39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jamda.2013.05.009","article-title":"Proinflammatory cytokines, aging, and age-related diseases","volume":"14","author":"Michaud","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaf048","article-title":"Disturbed functional connectivity between anterior default mode and sensory processing regions is linked to peripheral inflammatory markers and psychopathology in schizophrenia","volume":"52","author":"Mlynek","year":"2026","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.bbih.2026.101342_bib41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","article-title":"Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis","volume":"41","author":"Mondelli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(97)00036-X","article-title":"Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment","volume":"71","author":"Monteleone","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbih.2026.101342_bib43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.bbih.2026.101342_bib44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"Muller","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.bbih.2026.101342_bib45","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/schbul\/sby160","article-title":"A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis","volume":"45","author":"Pillinger","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.bbih.2026.101342_bib46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00004714-199610000-00011","article-title":"Effects of clozapine on plasma cytokine and soluble cytokine receptor levels","volume":"16","author":"Pollmacher","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbih.2026.101342_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2026.111701","article-title":"Microstructural and diffusion tensor imaging of clozapine for treatment-resistant schizophrenia","volume":"146","author":"Raminfard","year":"2026","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbih.2026.101342_bib48","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12035-019-01737-z","article-title":"The role of aberrations in the immune-inflammatory response system (IRS) and the compensatory immune-regulatory reflex system (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia","volume":"57","author":"Roomruangwong","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.bbih.2026.101342_bib49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/oxfordjournals.schbul.a033412","article-title":"How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia","volume":"25","author":"Rosenheck","year":"1999","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.bbih.2026.101342_bib50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.pnpbp.2006.09.013","article-title":"Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol","volume":"31","author":"Rothermundt","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.bbih.2026.101342_bib51","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1084\/jem.20100414","article-title":"IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages","volume":"207","author":"Smallie","year":"2010","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bbih.2026.101342_bib52","first-page":"137","article-title":"Greater choline-containing compounds and myo-inositol in treatment-resistant versus responsive schizophrenia: a (1)H-Magnetic resonance spectroscopy meta-analysis","volume":"9","author":"Smucny","year":"2024","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"issue":"2","key":"10.1016\/j.bbih.2026.101342_bib53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.pnpbp.2008.12.006","article-title":"Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice","volume":"33","author":"Sugino","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbih.2026.101342_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41537-024-00544-3","article-title":"Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow","volume":"10","author":"Sun","year":"2024","journal-title":"Schizophrenia (Heidelb)"},{"key":"10.1016\/j.bbih.2026.101342_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/02698811251409141","article-title":"Associations between glutamate and cerebral blood flow in treatment-resistant schizophrenia during clozapine treatment","author":"Sun","year":"2026","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.bbih.2026.101342_bib56","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/s41386-020-0665-4","article-title":"Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment","volume":"45","author":"Tronchin","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbih.2026.101342_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113772","article-title":"White matter microstructure and structural networks in treatment-resistant schizophrenia patients after commencing clozapine treatment: a longitudinal diffusion imaging study","volume":"298","author":"Tronchin","year":"2021","journal-title":"Psychiatry Res."},{"issue":"1\u20133","key":"10.1016\/j.bbih.2026.101342_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.bbih.2026.101342_bib59","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1017\/S0007114522002148","article-title":"Association between cytokine levels and anthropometric measurements: a population-based study","volume":"129","author":"Valmorbida","year":"2023","journal-title":"Br. J. Nutr."},{"issue":"3","key":"10.1016\/j.bbih.2026.101342_bib60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00213-022-06067-y","article-title":"Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine","volume":"239","author":"Yuan","year":"2022","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Brain, Behavior, & Immunity - Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354626001754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354626001754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:15:34Z","timestamp":1789157734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666354626001754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":60,"alternative-id":["S2666354626001754"],"URL":"https:\/\/doi.org\/10.1016\/j.bbih.2026.101342","relation":{},"ISSN":["2666-3546"],"issn-type":[{"value":"2666-3546","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine and C-reactive protein concentrations over 6 months of treatment with clozapine in treatment resistant schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, & Immunity - Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbih.2026.101342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101342"}}